| Catalog Number |
421982 |
| Medical Device Problem Code |
Incorrect, Inadequate or Imprecise Result or Readings (1535)
|
| Health Effect - Clinical Code |
No Patient Involvement (2645)
|
|
Type of Reportable Event
|
Malfunction
|
|
Event or Problem Description
|
|
A customer from the united states notified biomérieux of false resistant results for a cap survey strain (d-08) when testing with the vitek® 2 ast-gn95 test kit.The alcaligenes faecalis strain tested false resistant (mic >=128) for piperacillin/tazobactam using the ast-gn95 card, lot 6850485403.The expected result is susceptible.The customer did repeat testing and still obtained resistant results (mic >/=128) with the same lot.As there is no patient associated with this quality control strain, there is no adverse event related to any patient's state of health.A biomérieux internal investigation will be initiated.
|
| |
|
Additional Manufacturer Narrative
|
|
An internal investigation was performed for false resistant (mic >=128) piperacillin/tazobactam results for a alcaligenes faecalis cap survey strain (d-08) when testing with the vitek® 2 ast-gn95 test kit.The biomerieux cap d-08 survey strain was subcultured on tsab agar, and the identification was confirmed as a.Faecalis ssp faecalis.Testing included the ast-gn95 (6850485403) card lot as well as broth microdilution (bmd) as the reference method for tzp03n formulation found on all card types associated with this investigation.911704 (biomerieux internal d-08 strain): the ast-gn95 card was susceptible mic [= 4, and bmd was susceptible mic = 4.The ast-gn95 card and reference method are in agreement.Quality systems (qs) performed a search for all complaints against the ast-gn95 (6850485403) card lot associated with the complaint and no trends were observed.The vitek 2 ast-gn95 card and reference method are in agreement.The card performed as expected.
|
| |
|
Search Alerts/Recalls
|